On September 21, 2026, US spot Bitcoin ETFs attracted nearly $1 billion in a single day, the largest daily inflow in about a year, driven by Bitcoin's price briefly surpassing $87,000—the highest since January 2026. BlackRock's IBIT led with $381 million, followed by ARK 21Shares' ARKB and Fidelity's FBTC, together accounting for over 90% of the inflows. This surge reflects renewed investor confidence as Bitcoin holders return to profit after months of stagnant prices. The inflows are part of a broader trend, with August 2026 seeing $3.52 billion and September already reaching $1.31 billion in ETF investments, highlighting growing institutional interest facilitated by easier access through ETFs.
Bitcoin ETFs' nearly $1 billion inflow in a day is notable. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 22, 2026 21:22 WIB: out of 50 major cryptocurrencies priced on Pluang, 32 rose and 17 fell. Top movers include VET (VeChain) at Rp164 with a 6.34% increase, XRP (Ripple) at Rp28.012 up 6.32%, and EGLD (MultiversX) at Rp79.159 rising 6.01%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
